Loading…
Loading…
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the State Street SPDR S&P Biotech ETF (XBI), a passively managed exchange traded fund launched on January 31, 2006.
Both of these ETFs look the part, but only one is truly the better buy for investors.
Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction until you see what that same bet returned over five years.
Banque Pictet and Cie SA lowered its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 68.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 16,770 shares of the exchange traded fund's stock after selling 37,051 shares during the period. Banque Pictet
SPDR S&P Biotech ETF (NYSEARCA:XBI - Get Free Report) saw unusually large options trading activity on Thursday. Stock investors acquired 57,758 call options on the stock. This is an increase of approximately 47% compared to the average daily volume of 39,379 call options. Institutional Trading of SPDR S&P Biotech ETF A number of institutional investors
Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.
Ayalon Insurance Comp Ltd. grew its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 71.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,600 shares of the exchange traded fund's stock after acquiring an